Literature DB >> 20536375

Sensitivity and specificity of the 'Awaji' electrodiagnostic criteria for amyotrophic lateral sclerosis: retrospective comparison of the Awaji and revised El Escorial criteria for ALS.

Werner A Boekestein1, Bert U Kleine, G Hageman, Helenius J Schelhaas, Machiel J Zwarts.   

Abstract

The Awaji Commission recently proposed a modification of the electrodiagnostic criteria for ALS. We assessed whether the Awaji recommendations improve the sensitivity of the early diagnosis of ALS. In a retrospective study we reviewed clinical and neurophysiological data for 213 patients who visited our motor neuron disease outpatient clinic between October 2006 and December 2008. Using the El Escorial criteria, 51 patients were diagnosed with definite or probable ALS, 14 with probable laboratory-supported ALS, and 28 with possible ALS. An alternative diagnosis was present in 120 patients. Applying the Awaji recommendations, 66 patients were diagnosed with either definite or probable ALS, and 27 with possible ALS. Of the 14 patients diagnosed with probable laboratory-supported ALS, eight switched to probable ALS and six to possible ALS using the Awaji recommendations; none of the patients with an ALS mimic was diagnosed with ALS according to the Awaji recommendations. In conclusion, the new criteria for ALS do not result in a loss of specificity and can potentially improve the sensitivity by 16%. However, this diagnostic improvement appears eliminated if patients with probable laboratory-supported ALS - due to UMN signs in one region - should be categorized as possible ALS.

Entities:  

Mesh:

Year:  2010        PMID: 20536375     DOI: 10.3109/17482961003777462

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler        ISSN: 1471-180X


  8 in total

Review 1.  Challenges in the Understanding and Treatment of Amyotrophic Lateral Sclerosis/Motor Neuron Disease.

Authors:  Jeffrey Rosenfeld; Michael J Strong
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

2.  Utility of dissociated intrinsic hand muscle atrophy in the diagnosis of amyotrophic lateral sclerosis.

Authors:  Parvathi Menon; Steve Vucic
Journal:  J Vis Exp       Date:  2014-03-04       Impact factor: 1.355

3.  Evidence of synergism among three genetic variants in a patient with LMNA-related lipodystrophy and amyotrophic lateral sclerosis leading to a remarkable nuclear phenotype.

Authors:  Kathryn Volkening; Sali M K Farhan; Jessica Kao; Cheryl Leystra-Lantz; Lee Cyn Ang; Adam McIntyre; Jian Wang; Robert A Hegele; Michael J Strong
Journal:  Mol Cell Biochem       Date:  2021-03-04       Impact factor: 3.396

4.  The Awaji criteria increases the diagnostic sensitivity of the revised El Escorial criteria for amyotrophic lateral sclerosis diagnosis in a Chinese population.

Authors:  Da-Wei Li; Mingsheng Liu; Bo Cui; Jia Fang; Yu-Zhou Guan; Qingyun Ding; Xiaoguang Li; Liying Cui
Journal:  PLoS One       Date:  2017-03-01       Impact factor: 3.240

5.  Clinical and research applications of neuromuscular ultrasound in amyotrophic lateral sclerosis.

Authors:  Stephanie L Barnes; Neil G Simon
Journal:  Degener Neurol Neuromuscul Dis       Date:  2019-07-16

6.  Amyotrophic lateral sclerosis and the clinical potential of dexpramipexole.

Authors:  Philippe Corcia; Paul H Gordon
Journal:  Ther Clin Risk Manag       Date:  2012-08-27       Impact factor: 2.423

7.  The possible meaning of fractional anisotropy measurement of the cervical spinal cord in correct diagnosis of amyotrophic lateral sclerosis.

Authors:  Slawomir Budrewicz; Pawel Szewczyk; Joanna Bladowska; Ryszard Podemski; Ewa Koziorowska-Gawron; Maria Ejma; Krzysztof Słotwiński; Magdalena Koszewicz
Journal:  Neurol Sci       Date:  2015-11-21       Impact factor: 3.307

8.  The Gold Coast criteria increases the diagnostic sensitivity for amyotrophic lateral sclerosis in a Chinese population.

Authors:  Dongchao Shen; Xunzhe Yang; Yanying Wang; Di He; Xiaohan Sun; Zhengyi Cai; Jinyue Li; Mingsheng Liu; Liying Cui
Journal:  Transl Neurodegener       Date:  2021-08-09       Impact factor: 8.014

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.